Archimedes, Inc. Expands Use of Big Data in Healthcare Modeling and Analytics
News Mar 28, 2013
Archimedes, Inc., a healthcare modeling and analytics company, announced today that it is substantially expanding its modeling and analytics solutions. New product offerings and disease models will enable users to more quickly and easily access and analyze information related to their complex questions. Archimedes customers will be able to further enhance their modeling and analytic projects by integrating their own electronic health records (EHR), claims, clinical trial, and pharmacokinetic/pharmacodynamic (PK/PD) simulation outcomes data with data from Archimedes simulations and proprietary algorithms. This integrated data will be accessed and analyzed through novel interfaces that offer near-instant results.
For more than ten years, the company has been working to proactively identify new opportunities where big data can play a role in the healthcare continuum – from research and development to the point of patient care. The advancements, which will become available throughout 2013, represent Archimedes’ continued commitment to its vision of revolutionizing medicine worldwide through mathematics.
“At Archimedes, we are dedicated to harnessing the power of big, real-world data by developing healthcare modeling and analytics tools,” said David Eddy, M.D., Ph.D. founder of Archimedes and pioneer in the area of evidenced-based medicine. “We are continually developing tools that can help researchers, life-science organizations, government agencies, payers, and providers get the most from the available data. Archimedes is excited to announce that, starting today, we will be providing free access through our website to new, easy-to-use tools for addressing some of healthcare’s most complex questions.”
Since inception, Archimedes has been striving to improve efficiencies in the healthcare system by developing quantitative methods for analyzing healthcare decisions at the individual and population levels. The tools, including the new ARCHeS Population Explorer, take modeling and analytics a step further by delivering big data to the fingertips of users, making it easier and faster to gather, enhance, and analyze multiple datasets. In the current era of accountability in medical decision making, it is critical that actionable data analytics tools are made available to the people who need them most.
The Archimedes Model is the most advanced mathematical modeling tool available to answer complex questions regarding health and healthcare. It is a clinically realistic, trial-validated, mathematical model of human physiology, diseases, interventions, and healthcare systems. By using advanced methods of mathematics, computing, and data systems, the Model enables researchers and decision makers to make better informed decisions. Archimedes continually validates the Model by comparing the results of simulated trials to the results of multinational clinical trials and cohort studies. The Model is the foundation behind the various solutions offered by Archimedes – including ARCHeS, the population-focused research platform, and IndiGO, the clinical-decision support tool for use by physicians and patients at the point-of-care.
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE